Three-Year Outcomes Of A Novel Toric Intraocular Lens Implantation For Moderate-High Myopic Astigmatism In Phakic Eyes
Published 2022
- 40th Congress of the ESCRS
Reference: FPM07.11
| Type: Free paper
| DOI:
10.82333/swvx-4388
Authors:
Yusuf Berk Akbas* 1
, Burcin Kepez Yildiz 1
, Mehmet Emin Sucu 2
, Alper Agca 3
, Ugur Tunc 4
, Yusuf Yildirim 1
1Ophthalmology,Beyoglu eye training and research hospital,ISTANBUL,Türkiye, 2Ophthalmology,İdil state hospital,Şırnak,Türkiye, 3Ophthalmology,Ataköy Dünya Göz Hospital,ISTANBUL,Türkiye, 4Ophthalmology,Eyupsultan State Hospital,ISTANBUL,Türkiye
Purpose
To investigate long term adverse events, refractive and visual outcomes of Eyecryl toric phakic IOL (pIOL) for moderate to high myopic astigmatism
Setting
Beyoglu Eye Training and Research Hospital, University of Health Science, ISTANBUL, TURKEY
Methods
The efficacy, safety, predictability, stability, vector analysis and adverse events of Eyecryl toric pIOL were evaluated in patients with spherical refraction from -4.50 to -18.50 diopters (D) and cylindrical refraction from -0.50 to -5.50 D.
Results
Fifty-five eyes of 29 patients were included in the study. The mean manifest refraction spherical equivalent was -10.46±3.16 D and -0.60±0.61 D at preoperatively and postoperative 36. month, respectively. At the last visit, all eyes except one eye were within ±2.00 D of the desired MRSE, and number of eyes within ±1.00 D and ±0.50 D were 44 (80%) and 31 (56.4%), respectively. The efficacy index was 1.11±0.35, the safety index was 1.36±0.42 at 36 months postoperatively. At last visit, one eye who developed central anterior subcapsular opacity (1.8%) had lost 2 lines of corrected distance visual acuity (CDVA), two eyes (3.6%) developed visually non significant anterior subcapsular opacites and 65.4% of eyes had gained at least 1 line of CDVA.
Conclusions
The Eyecryl toric pIOL demonstrated relatively a good visual acuity and refractive results regarding the efficacy index and the safety index in long term period.